Opus Genetics (IRD) President Yerxa Sells $117K of Stock
Key Points
- Benjamin Yerxa, President of Opus Genetics, sold 33,189 shares at an average price of $3.54 on October 23, 2026, lowering his ownership by 4.71%.
- After the trade, Benjamin R Yerxa holds 670,917 $IRD shares, down 4.71% from before the trade.
- The stock closed at $3.47 on the same day, while it has recently traded around $3.46, which is about 51.1% below its 52-week high of $7.07.
- Analysts remain optimistic, with a consensus rating of 'strong buy' and a mean price target of $13.47, significantly above the recent trading price.
Since the trade, $IRD is down 0.3% to date (from the $3.47 close on Oct 23, 2026).
Get Opus Genetics text alerts
We text you when insiders, Congress, analysts or big funds move on $IRD.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Opus Genetics, Inc. alert may contain errors. Disclosures
Benjamin Yerxa, President of Opus Genetics, Inc. (ticker: IRD), sold 33,189 shares of the company on October 23, 2026, for approximately $117,366. This sale reduces his stake by about 4.71%. The details of the trade were reported in a Form 4 filing with the SEC.
Yerxa's sale comes as Opus Genetics continues to develop gene therapies aimed at restoring vision in patients with inherited retinal diseases. After the sale, he holds 670,917 shares of the company.
IRD
Opus Genetics, Inc.
Benjamin R Yerxa vs. the S&P 500
Hypothetical returns from Benjamin R Yerxa's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Opus Genetics
Caligan Partners, LP holds 6,077,084 shares of Opus Genetics, valued at about $21.0 million, having not changed its position. Adage Capital Partners GP L.L.C. remains steady with 6,029,775 shares worth approximately $20.9 million. Bios Capital Management, LP also kept its holdings unchanged at 3,683,429 shares valued at around $12.7 million. Meanwhile, Balyasny Asset Management LP increased its stake by 369,913 shares, now owning 3,087,866 shares worth about $10.7 million. Nantahala Capital Management, LLC boosted its holdings significantly by 1,380,033 shares, bringing its total to 3,061,359 shares valued at about $10.6 million.
Opus Genetics, Inc. Stock Up 4.2%
The stock of Opus Genetics closed at $3.47 on October 23, 2026, and has recently traded around $3.46, which is below its 50-day moving average of $4.49. The shares are currently more than 51% lower than their 52-week high of $7.07, but remain above the 52-week low of $1.70.
Recent Earnings
Opus Genetics reported trailing twelve-month revenue of $9.86 million, but its earnings per share (EPS) stood at -$1.27. The next earnings report is expected on November 11, 2026.
Insider Buying and Selling at Opus Genetics, Inc.
On the same day as Yerxa's sale, CEO George Magrath sold 9,591 shares for about $34,384, and CFO Robert E. Gagnon sold 14,000 shares for approximately $49,649. These transactions reflect ongoing adjustments by the company's leadership.
Analysts Set New Price Targets
On October 22, 2026, Chardan Capital maintained a Buy rating with a price target of $16.00. Citizens reiterated a Market Outperform rating on October 16, also with a target of $17.00. The consensus among analysts is a strong buy with a mean price target of $13.47, indicating confidence in the company’s future performance.
About Opus Genetics
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company based in Durham, NC, focused on developing gene therapies to treat inherited retinal diseases. Its lead products are in clinical trials aimed at addressing early-onset retinal degeneration and other ophthalmic disorders.
Bottom Line
Investors should monitor Opus Genetics as it approaches its earnings date on November 11, 2026, and watch for any further insider trading activity. The company’s stock remains significantly below analyst price targets, suggesting potential for future growth.
Related Filing Alerts
Source: Benjamin R Yerxa's Form 4 filing on $IRD (Oct 23, 2026). Written by software, not financial advice. How we make alerts